Pharmacist who’s amassed malaria drugs has ear of Utah leaders about COVID-19 treatment
(John Locher | AP file photo) This April 6, 2020, file photo shows an arrangement of hydroxychloroquine pills in Las Vegas. President Donald Trump and his administration kept up their out-sized promotion Monday of an malaria drug not yet officially approved for fighting the new coronavirus, even though scientists say more testing is needed before it’s proven safe and effective against COVID-19. Trump trade adviser Peter Navarro championed hydroxychloroquine in television interviews a day after the president publicly put his faith in the medication to lessen the toll of the coronavirus pandemic.
A Utah pharmacist says he has amassed ingredients for medication to use against the coronavirus and has talked with state leaders about a distribution plan, even as health experts across the nation stress the meager evidence of the malaria drug’s efficacy.
The stockpile of drug components could translate into 100,000 courses of treatment for coronavirus patients in Utah, says Meds in Motion owner Dan Richards, who hopes the unproven medication will quell fears that are keeping businesses shuttered and people indoors during the pandemic.
“If we shut down the economy for the next six months there could be as many people who die by suicide as die by the virus,” he said. “So we have to marry economics and medicine.”
Richards says he’s been in talks with the Utah Department of Health about putting his pills in local pharmacies, with the goal of making sure anyone in the state is within an hour of them.
Gen. Jeff Burton, the leader of the state’s coronavirus response team
, confirmed that he’s spoken with Richards about potentially “procuring the medication as a top priority and then determining how to get the medication into pharmacies,” a health department spokesman wrote in a text message Tuesday. However, no agreement with the health department has been finalized, spokesman Tom Hudachko added.
Richards has also established a relationship with Senate President Stuart Adams, a strong believer in the drugs’ potential.
Adams and Richards appeared together to promote the medications during a March news conference at the Utah Capitol, where an occupational health physician invoked the biblical resurrection story of Lazarus
in describing the drugs’ alleged ability to pull coronavirus patients back from the brink of death.
Meanwhile, the state’s infectious disease experts have consistently cautioned that there is scant evidence
for the anti-malaria medicine’s effectiveness in combatting COVID-19. The excitement about the drugs is largely built on anecdote, as the few scientific studies on the subject have produced conflicting results
, and many have questioned the quality of the research
There have been no rigorous clinical trials on using the medicine
, hydroxychloroquine and chloroquine, to treat coronavirus. And while hospitals in Utah are administering it to some gravely ill COVID-19 patients, many doctors are wary of prescribing the drugs to people who can manage their symptoms at home.
That’s in part because the medication can cause fatal heart arrhythmia and even cardiac arrest, said Scott Benson, an infectious disease specialist and faculty member at the University of Utah Health. Even one dose can trigger these dangerous changes in heartbeat, which is why taking the medication under supervision is so important for coronavirus patients, he said.
“At the moment, the appropriate use of these medications is in critically ill individuals ... that are hospitalized and monitored by a team of health care providers, nurses and pharmacists,” he said.
(AP business wire file photo) Gopesh Patel, RPh, with VLS Pharmacy in Brooklyn, has filled physician prescriptions for more than 70 COVID-19 patients, supplying a compounded formulation with hydroxychloroquine.
Isaac Noyes, incoming president of the Utah Academy of Family Physicians, said the drugs’ side effects are rare but can be serious, adding that medical providers have varying comfort levels about prescribing hydroxychloroquine and chloroquine for coronavirus. Everyone hopes the medications will be beneficial, but he agrees with Benson that in the absence of evidence, the drugs are best reserved for very ill patients in the hospital.
“Widespread distribution and prescribing of these for the vast majority of people probably poses a risk that’s equal to or greater than the benefit they’d see,” he said.
Intermountain Healthcare and University of Utah Health physicians recently announced they were launching a pair of clinical trials of hydroxychloroquine
, making the medication available to about 2,300 coronavirus patients under strict supervision. However, one of the physicians spearheading the research cautioned against expecting the drug to work miracles.
“The likelihood is that hydroxychloroquine does not have an effect,” Samuel Brown, critical care researcher at Intermountain, said Wednesday during a virtual news conference. “We hope it might have a moderate effect, but that’s not at all clear.”
Brown also enumerated the potential pitfalls of widespread prescription outside the bounds of a clinical trial — explaining that if the drug doesn’t do anything to treat COVID-19, then there’s no reason to run the risk of possible side effects.
But Richards believes the drugs should be broadly available to Utahns, noting that they’ve long been prescribed for people who have lupus and rheumatoid arthritis
While there’s plenty research left to do on the medication, Richards argues the cost of doing nothing outweighs the potential risks of making the drugs accessible. Fear is immobilizing the economy, he argues, and prolonging the freeze will only compound the damage done by COVID-19.
“The economy is dying,” he said. “So, what good is it to survive the virus and have the economy die?”
However, Noyes said it would be dangerous to give people a “false sense of security” that the medications will magically cure coronavirus or curtail its spread. While he, too, worries about the economic ravages of the virus, his group has advocated for a statewide stay-at-home order as the fastest way of controlling the disease
and reopening businesses.
“I don’t think [the drug] is the magic bullet that’s going to allow the country to open back up sooner,” he said.
Debate over the medication in Utah is a microcosm of the national controversy over the drugs, touted by conservative television personalities and President Donald Trump as a possible game changer in the pandemic
“What do you have to lose?” Trump asked reporters last Sunday
, after his medical experts cautioned against overhyping the medication.
The American Medical Association, American Pharmacists Association and American Society of Health-System Pharmacists have issued a joint statement discouraging hospitals and pharmacies from stockpiling the drugs
, noting that there is “no incontrovertible evidence to support off-label use of medications for COVID-19.” Panic buying also reduces the availability of medication for lupus patients and others who have long relied on it, the statement continued.
In Utah, Richards has been in talks with an informal yet influential group of businesspeople and state lawmakers about treatment and testing strategies for COVID-19. Realizing the anti-malaria drugs were in short supply in some places, Richards bought massive quantities of powder to produce the medication, and he says he’s about to begin making capsules.
Because Meds in Motion only has five locations across Utah, Richards wants to craft a wider distribution plan in conjunction with state health officials.
No one is pressuring medical providers to use the unproven drugs for coronavirus, says Adams, who along with Richards and Sen. Kirk Cullimore, R-Draper, is part of the informal group that has talked about medication options. Adams says he and other officials are just trying to make sure the medication is in stock if physicians do want to prescribe it.
“Whether someone takes the medication or not, it should be up to their health care provider, and they should be given the information that’s appropriate for them to make that decision,” Adams, R-Layton, said. “This drug ... may work, it may not work.”
Adams said the state might not have to work with Richards to replenish pharmacies and that — with 2,300 reported coronavirus cases in Utah — the existing supply chain might be adequate. If there are shortages, he said, officials might turn to Meds in Motion.
Maryann Martindale, executive director of Utah Academy of Family Physicians, said she would urge state leaders not to give undue consideration to businesses that stand to profit from their decisions. That concern is especially relevant during the pandemic, she said, whether or not it applies in Richards’ case.
“We really need to proceed with full transparency and make sure that everything is beyond question,” she said. “As a citizen and as a taxpayer, I would be very concerned that someone is looking to influence decisions while also profiting from that decision. I think that’s a dangerous road to go down.”
The state’s health department has not advised physicians to prescribe the medicine, although it has released guidance on the dosage for doctors
who want to use it. Utah health officials briefly floated the possibility of letting people pick up the drugs without a prescription but backed away from that idea
Adams said it would be a tragedy if the state forged ahead with a medication that did no good, but it would be equally tragic if Utah didn’t explore a potential remedy for coronavirus patients.
His opinion on the medications has been shaped by initial studies and anecdotes that have suggested it could help in COVID-19 cases, he said, not by Richards or others in the business. He cited news stories about doctors who have reported success with the medication
and a conversation with a neighbor, whose friend contracted the infection and benefited from hydroxychloroquine.
And he noted that the nation’s commander-in-chief has been an aggressive promoter.
“Why is the president speaking about it?” Adams, one of Utah’s first supporters of Trump
, said. “There must be somebody, somewhere who’s getting better."